Close Menu

NEW YORK (GenomeWeb) – Amarantus BioScience Holdings today said that it closed on a $5 million investment from privately held mutual fund Discover Growth Fund. 

Amarantus plans to use the financing to further develop and commercialize its neurology diagnostic products and therapeutic drug candidates, and for other working capital expenses, it said. In conjunction with the investment, the San Francisco-based company issued a new class of preferred stock, Series G, that is convertible into Amarantus' common stock at a fixed price of $.06 per share. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
23
Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.